Loading
Pablo Legorreta received $938K in total compensation as Chief Executive Officer of Royalty Pharma plc in FY2025. The largest component was $938K in base salary. That’s down 97% from FY2024. Source: SEC DEF 14A.
In fiscal year 2025, Pablo Legorreta, Chief Executive Officer of Royalty Pharma plc (RPRX), received total compensation of $938K.
Pablo Legorreta's compensation breakdown includes: base salary of $938K,.
Compared to fiscal year 2024, Pablo Legorreta's total compensation decreased 97% from $31.2 million to $938K.
Royalty Pharma plc's top 5 named executive officers received combined total compensation of $6.2 million in fiscal year 2025.
The named executive officers disclosed in Royalty Pharma plc's 2025 proxy statement are:Pablo Legorreta (Chief Executive Officer) with total compensation of $938K, Terrance Coyne (Executive Vice President & Chief Financial Officer) with total compensation of $1.3 million, Christopher Hite (Executive Vice President & Vice Chairman) with total compensation of $1.3 million, George Lloyd (Former Executive Vice President Chief Legal Officer & Investments) with total compensation of $1.3 million, and Marshall Urist (M.D., Ph.D. Executive Vice President, Research & Investments) with total compensation of $1.3 million.
Pablo Legorreta, Chief Executive Officer of Royalty Pharma plc (RPRX), received $937,500 in total compensation for FY2025, down 97.0% from the prior year. Base salary of $937,500 was the largest component. Figures come from Royalty Pharma plc's DEF 14A 0001140361-26-014239 filed 10 Apr 2026.
Source Filing
Executive Record
Pablo Legorreta
Chief Executive Officer
Reported Pay
$938KSummary compensation table total · FY2025
Findings
Reviewing FY2025 compensation of $938K against +39% shareholder return and the latest filing-backed pay disclosures.
Reported pay changed -97%; spread versus stock performance is pending computation.
Evidence is sourced from the latest executive compensation filing and return series for RPRX.
Royalty Pharma plc (RPRX) — Key Facts
Last updated Aug 28, 2026 · DEF 14A filed Apr 10, 2026
| CEO | Pablo Legorreta, Chief Executive Officer |
|---|---|
| Fiscal year | FY2025 |
| Total compensation | $938K |
| Base salary | $938K |
| Year-over-year change | -97% |
| Source | DEF 14A, 2026-04-10 |
Pablo Legorreta, the Chief Executive Officer of Royalty Pharma plc, received total compensation of $937,500 in fiscal year 2025. This includes base salary of $937,500. Figures come from Royalty Pharma plc's DEF 14A 0001140361-26-014239 filed 10 Apr 2026.
Pablo Legorreta's base salary at Royalty Pharma plc is $937,500 per year as of fiscal year 2025. However, total compensation including stock awards, bonuses, and other benefits is $937,500. Figures come from Royalty Pharma plc's DEF 14A 0001140361-26-014239 filed 10 Apr 2026.
Royalty Pharma plc's CEO, Pablo Legorreta, earned $937,500 in total compensation for fiscal year 2025. Figures come from Royalty Pharma plc's DEF 14A 0001140361-26-014239 filed 10 Apr 2026.
Reading filings for RPRX...
Reading the latest proxy statement
Calculating CEO-to-worker ratio
Checking insider sales and trading plans